The Graft-Versus-Myeloma Effect: Chronic Graft-Versus-Host Disease but Not Acute Graft-Versus-Host Disease Prolongs Survival in Patients with Multiple Myeloma Receiving Allogeneic Transplantation
Michèle L. Donato(The University of Texas Health Science Center at Houston), Scott D. Rowley(Johns Hopkins Hospital), Phyllis McKiernan(Hackensack University Medical Center), David S. Siegel(Hackensack Meridian Health), Andrew L. Pecora(Hackensack University Medical Center), Themba Nyirenda(Hackensack University Medical Center), Melissa Baker(Hackensack University Medical Center), André Goy(Hackensack University Medical Center), Anthony R. Mato(University of Pennsylvania), Stuart L. Goldberg(Hackensack University Medical Center), David H. Vesole(Hackensack University Medical Center)
Cited by 54
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2020|1.9k
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2019|1.7k
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2013|1.7k